Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RDH098
- Development stage
- Preclinical
- Lead developer
- Apichope Pharmaceutical
- Modality
- Small Molecules
01
Overview
RDH098 is a small molecule drug candidate under development by Apichope Pharmaceutical (also known as Yipinhong) for the treatment of respiratory system diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Classified as a Class 1 innovative drug in the developer's pipeline, RDH098 is currently in the preclinical stage of development, where it is undergoing pharmaceutical research and safety evaluations. While the specific biological target and molecular mechanism of action have not been publicly disclosed, the compound represents a key asset in Apichope's expansion into the respiratory therapeutic space.
02
Targets
GPR84
Beyond the preview
Go deeper on RDH098.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RDH098.